Condiciones de salud que ferula assafoetida puede ayudar a apoyar.
The PMC6129344 RCT found that asafoetida formulation (Asafin) produced significant and clinically meaningful reduction in abdominal discomfort, bloating, and postprandial fullness in 43 adults with functional dyspepsia over 30 days, with 66% symptom-free at study end. Traditional use is pervasive across Ayurveda and Middle Eastern medicine.
A randomized, double-blind, placebo-controlled trial (PMC6129344) tested a food-grade asafoetida formulation (Asafin) in 43 adults with non-ulcer functional dyspepsia. At 500 mg/day for 30 days, 81% of the treatment group showed significant improvement in overall symptom scores including heartburn and bloating, versus less than 10% in the placebo group. The smooth-muscle relaxant and carminative mechanisms of asafoetida are thought to reduce acid-related upper GI discomfort.
Asafoetida's antioxidant activity is established through multiple in vitro studies, animal models, and indirect human data via ferulic acid RCTs. Key constituents including ferulic acid, sulfur compounds, and sesquiterpene coumarins scavenge free radicals and upregulate endogenous antioxidant enzymes.
A preclinical rodent study (ResearchGate, Anxiolytic effect of Ferula assafoetida L.) demonstrated dose-dependent anxiolytic and mild sedative effects of asafoetida extract using elevated plus-maze and hole-board tests, with comparison against diazepam. Traditional use across Ayurvedic, Unani, and Iranian medicine also documents asafoetida as a sedative and nervine. No controlled human clinical trials for anxiety alone have been published.
Asafoetida contains coumarins that are documented to inhibit blood clotting and thin the blood. Pharmacological reviews state it 'thins the blood and lowers blood pressure.' Coumarins in asafoetida may also enhance the activity of anticoagulant drugs such as warfarin.
Animal research has shown that F. asafoetida gum extract significantly reduces average arterial blood pressure. Multiple pharmacological reviews classify asafoetida as hypotensive. Traditional herbalism in Ayurveda and Unani also documents blood-pressure-lowering properties.
Multiple animal studies demonstrate that Ferula asafoetida oleo-gum-resin extract significantly lowers blood glucose in streptozotocin-induced diabetic rats. Antidiabetic activity is attributed to ferulic acid and tannins. A PCOS clinical trial also measured fasting blood sugar as a secondary outcome. Human clinical evidence is limited.
In vitro studies show that aqueous and alcoholic extracts of asafoetida inhibit Candida albicans growth, though MIC values are higher than standard antifungal drugs. Asafoetida also inhibits Aspergillus flavus. Activity is attributed to its organosulfur compounds, coumarins, and flavonoids.
Preclinical studies in diabetic rat models show F. asafoetida extract significantly reduces total cholesterol and LDL-C while increasing HDL-C. Ferulic acid (a key asafoetida constituent) reduced total cholesterol by 8.1% and LDL-C by 9.3% in a human RCT in hyperlipidemic subjects.
Asafoetida oleo-gum-resin suppresses key pro-inflammatory mediators including TNF-α, IL-6, and IL-1β in cell-based studies (PMC9453118). Multiple Ferula species reviews document anti-inflammatory activity through lipoxygenase inhibition and ROS scavenging. Clinical trial data on chronic inflammation as a primary endpoint are not yet available.
Asafoetida has been shown to facilitate digestion by promoting the activities of digestive enzymes in the pancreas and small intestine and stimulating bile acid production. These effects are documented in preclinical studies and support its classification as a digestive aid in Ayurveda.
Two small clinical studies in IBS adults found significant improvement in symptoms with asafoetida supplementation; however, a third study found no effect (Healthline). The PMC6129344 RCT in functional dyspepsia—which overlaps with IBS symptomatology—strongly supports gastrointestinal smooth-muscle modulation. Asafoetida is a primary Ayurvedic IBS remedy.
Asafoetida is a documented emmenagogue across Ayurvedic, Persian, and Unani medicine, used to stimulate and regulate menstruation. A human double-blind RCT compared asafoetida (1 g/day) versus oral contraceptive in 30 PCOS patients, assessing menstrual regularity and ovarian status as primary outcomes.
Animal studies consistently demonstrate hepatoprotective activity of F. asafoetida extracts, including reduction of elevated liver enzymes (ALT, AST, ALP) in models of chemical-induced hepatotoxicity. A 2025 PMC review specifically examined asafoetida's protective effects on the liver against formaldehyde-induced damage.
A rat study (PMC3271546) showed that F. asafoetida gum extract produced dose-dependent improvement in memory on elevated plus-maze and passive avoidance models, alongside dose-dependent inhibition of brain cholinesterase. A 2024 human RCT also found secondary improvements in cognitive attention with asafoetida supplementation.
In the RCT on functional dyspepsia (PMC6129344), the Asafin formulation produced 75% improvement in motion sickness (nausea) scores in the treatment group versus less than 10% in placebo. Traditional use also includes nausea associated with indigestion.
Animal studies in diabetic rat models demonstrate that F. asafoetida oleo-gum-resin extract significantly reduces plasma triglycerides alongside total cholesterol and LDL-C. A PCOS human RCT measured triglycerides as a secondary outcome with asafoetida treatment. Ferulic acid, a key constituent, reduced triglycerides by 12.1% in a human RCT.
Animal studies demonstrate that asafoetida combined with fenugreek exhibits significant gastric protection in ethanol-induced ulcer rat models. A Ferula plant extract study in rats (PMC12311313) showed reduced ulcerative area and suppressed TNF-α and p53 with treatment. Traditional use for ulcers is documented in Afghanistan and Indian medicine.
Asafoetida is a traditional Ayurvedic, Unani, and European remedy for asthma. Its antispasmodic, bronchodilatory, and expectorant properties—mediated by elimination of volatile oil through the lungs and tracheal smooth-muscle relaxation—provide pharmacological plausibility. Animal smooth-muscle studies support bronchodilatory effects.
Chronic bronchitis is a primary traditional indication for asafoetida documented across Ayurvedic, Unani, European, and Middle Eastern medicine. Expectorant activity via pulmonary elimination of volatile oil, smooth-muscle relaxation, and antimicrobial properties underpin this use.
Asafoetida has been used in traditional medicine across the Middle East, South Asia, and North Africa as a remedy for infant colic and flatulent colic in adults. It was historically employed for infantile colic and pneumonia. Use in infants carries a documented safety risk (methemoglobinemia has been reported in neonates) and is not recommended clinically.
Asafoetida oleo-gum resin is classified as a laxative in traditional herbalism, including Ayurveda, European, and Middle Eastern systems. The gum resin is documented as 'antispasmodic, carminative, expectorant, laxative, and sedative' across multiple authoritative herbal reviews. No human clinical trials targeting constipation specifically have been published.
In traditional medicine systems, asafoetida is used for both constipation and diarrhea-predominant gastrointestinal complaints. Its antispasmodic and antimicrobial properties underpin its use for loose stools and gut dysbiosis. Small IBS clinical studies include both diarrhea and constipation phenotypes.
Asafoetida is listed as an anti-epileptic in Moroccan pharmacopeia (where gum is chewed as antiepileptic) and in multiple global traditional medicine systems. Preclinical data show ferulic acid (a key asafoetida constituent) has anticonvulsant effects via GABAergic and nitric oxide pathways in rodent seizure models.
Asafoetida is traditionally classified as hepatopathic and splenopathic in Ayurvedic medicine and is used in conditions affecting the gallbladder and liver. It is documented as stimulating bile acid production, which is directly relevant to gallbladder function and bile flow.
Asafoetida is classified as antispasmodic and emmenagogue in Ayurvedic, Unani, and Iranian medicine and is specifically used for painful menstruation (dysmenorrhea) and uterine cramps. Smooth muscle relaxant activity confirmed in guinea pig ileum studies supports the mechanistic basis for uterine antispasmodic effects.
Asafoetida is consistently described as an expectorant in traditional herbalism, including European, Ayurvedic, Unani, and Middle Eastern medicine. The volatile oil of the resin is eliminated through the lungs, directly acting on bronchial secretions to loosen and expel mucus and phlegm.
Asafoetida is documented as a vermifuge and anthelmintic across Chinese, Egyptian, Nepalese, and Middle Eastern traditional medicine. Decoctions are taken orally as a vermifuge in China; aqueous extracts as anthelmintic in Nepal. In vitro evidence also shows activity against Trichomonas vaginalis.
Whooping cough (pertussis) is a primary traditional indication for asafoetida in Saudi Arabia, Afghanistan, India, and European herbalism. Its antispasmodic and expectorant properties are considered the basis for reducing paroxysmal coughing fits.
Asafoetida has been used in traditional herbalism for hoarseness and sore throat, listed among its traditional indications by RxList and multiple ethnopharmacological sources. Its antimicrobial and anti-inflammatory properties provide a mechanistic basis.
Asafoetida is one of the most widely documented traditional remedies for upper and lower respiratory conditions, including bronchitis, asthma, whooping cough, and influenza, across Ayurvedic, Unani, European, and Middle Eastern medicine. Its expectorant mechanism involves elimination of volatile oil through the lungs.
Volver